Lexicon Pharmaceuticals, Inc. lost $0.14 per diluted share in fiscal year 2025. This represents an increase of 77.8% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.15 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Lexicon Pharmaceuticals, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.14
YoY+77.8%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
LXRX EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Lexicon Pharmaceuticals, Inc.'s diluted earnings per share in fiscal year 2025?
Lexicon Pharmaceuticals, Inc. lost $0.14 per diluted share in fiscal year 2025.
How fast is Lexicon Pharmaceuticals, Inc.'s diluted earnings per share growing?
Lexicon Pharmaceuticals, Inc. (LXRX) diluted earnings per share rose by 77.8% year over year, from -$0.63 to -$0.14 in fiscal year 2025.
What is Lexicon Pharmaceuticals, Inc.'s diluted earnings per share over the last twelve months?
Lexicon Pharmaceuticals, Inc. (LXRX) reported a loss of $0.15 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Lexicon Pharmaceuticals, Inc.'s diluted earnings per share in the most recent quarter?
Lexicon Pharmaceuticals, Inc. (LXRX) reported -$0.07 in diluted earnings per share in Q2 2026. This represents a decrease of 800.0% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Lexicon Pharmaceuticals, Inc. (LXRX) reported on that line in every period on record.
